Lexicon Pharmaceuticals to Get $25 Million From Viatris in Global Sotagliflozin Licensing Deal

MT Newswires Live

Oct 17, 2024

Lexicon Pharmaceuticals (LXRX) will get an upfront payment of $25 million from Viatris (VTRS) for an exclusive license to commercialize sotagliflozin outside of the US and Europe in all indications.

Sotagliflozin is a medication used to reduce the risk of death and hospitalization in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. The drug was approved the US Food and Drug Administration in May 2023, Lexicon said Wednesday in a statement.

Under the licensing accord, Lexicon is eligible for potential regulatory and sales milestone payments as well as tiered royalties on annual net sales.

Lexicon holds sole commercialization rights for the drug in the US and Europe. The company will provide clinical and commercial supply of sotagliflozin to Viatris at a transfer price.

Shares of Lexicon fell 1% in recent after-hours activity, and Viatris dropped 0.2% in the regular session.

Price: 1.8900, Change: -0.02, Percent Change: -1.05

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2476747970"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2476747970\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2476747970?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-17 05:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2476747970","market":"hk","top_or_hot":-1,"title":"Lexicon Pharmaceuticals to Get $25 Million From Viatris in Global Sotagliflozin Licensing Deal","media":"MT Newswires Live","content":"<html><body><p> Lexicon Pharmaceuticals (LXRX) will get an upfront payment of $25 million from Viatris (VTRS) for an exclusive license to commercialize sotagliflozin outside of the US and Europe in all indications.</p><p>Sotagliflozin is a medication used to reduce the risk of death and hospitalization in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. The drug was approved the US Food and Drug Administration in May 2023, Lexicon said Wednesday in a statement.</p><p>Under the licensing accord, Lexicon is eligible for potential regulatory and sales milestone payments as well as tiered royalties on annual net sales.</p><p>Lexicon holds sole commercialization rights for the drug in the US and Europe. The company will provide clinical and commercial supply of sotagliflozin to Viatris at a transfer price.</p><p>Shares of Lexicon fell 1% in recent after-hours activity, and Viatris dropped 0.2% in the regular session.</p><p>Price: 1.8900, Change: -0.02, Percent Change: -1.05</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lexicon Pharmaceuticals to Get $25 Million From Viatris in Global Sotagliflozin Licensing Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLexicon Pharmaceuticals to Get $25 Million From Viatris in Global Sotagliflozin Licensing Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-10-17 05:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Lexicon Pharmaceuticals (LXRX) will get an upfront payment of $25 million from Viatris (VTRS) for an exclusive license to commercialize sotagliflozin outside of the US and Europe in all indications.</p><p>Sotagliflozin is a medication used to reduce the risk of death and hospitalization in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. The drug was approved the US Food and Drug Administration in May 2023, Lexicon said Wednesday in a statement.</p><p>Under the licensing accord, Lexicon is eligible for potential regulatory and sales milestone payments as well as tiered royalties on annual net sales.</p><p>Lexicon holds sole commercialization rights for the drug in the US and Europe. The company will provide clinical and commercial supply of sotagliflozin to Viatris at a transfer price.</p><p>Shares of Lexicon fell 1% in recent after-hours activity, and Viatris dropped 0.2% in the regular session.</p><p>Price: 1.8900, Change: -0.02, Percent Change: -1.05</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2476747970","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2476747970","pubTimestamp":1729115638,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Lexicon Pharmaceuticals (LXRX) will get an upfront payment of $25 million from Viatris (VTRS) for an exclusive license to commercialize sotagliflozin outside of the US and Europe in all indications.So","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","VTRS":"Viatris Inc.","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","BK4139":"生物科技","BK4583":"猴痘概念","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","BK4007":"制药","LXRX":"莱斯康制药","BK4588":"碎股"},"translate_title":"Lexicon Pharmaceuticals将在全球Sotagliflozin许可协议中从Viatris获得2500万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LXRX":1,"VTRS":0.9},"content_text":"Lexicon Pharmaceuticals (LXRX) will get an upfront payment of $25 million from Viatris (VTRS) for an exclusive license to commercialize sotagliflozin outside of the US and Europe in all indications.Sotagliflozin is a medication used to reduce the risk of death and hospitalization in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. The drug was approved the US Food and Drug Administration in May 2023, Lexicon said Wednesday in a statement.Under the licensing accord, Lexicon is eligible for potential regulatory and sales milestone payments as well as tiered royalties on annual net sales.Lexicon holds sole commercialization rights for the drug in the US and Europe. The company will provide clinical and commercial supply of sotagliflozin to Viatris at a transfer price.Shares of Lexicon fell 1% in recent after-hours activity, and Viatris dropped 0.2% in the regular session.Price: 1.8900, Change: -0.02, Percent Change: -1.05","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}